References
- Franko J, Shi Q, Meyers JP, et al. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17:1709–19.
- Goéré D, Malka D, Tzanis D, et al. (2013). Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065–71.
- Verwaal VJ, van Ruth S, de Bree E, et al. (2003). Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal metastasis of colorectal cancer. J Clin Oncol 15:3737–43.
- Verwaal VJ, Bruin S, Boot H, et al. (2008). 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal metastasis of colorectal cancer. Ann Surg Oncol 15:2426–32.
- Glockzin G, Rochon J, Arnold D, et al. (2013). A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 13:67.
- Cashin PH, Mahteme H, Spång N, et al. (2016). Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 53:155–62.
- Votanopoulos K, Ihemelandu C, Shen P, et al. (2013). A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179:e133–9.
- Sgarbura O, Samalin E, Carrere S, et al. (2016). Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. Pleura Peritoneum 1:209–15.
- Klaver CEL, Musters GD, Bemelman WA, et al. (2015). Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 15:428.
- Sloothaak DAM, Gardenbroek TJ, Crezee J, et al. (2017). Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. Eur J Surg Oncol (to be published)
- Sammartino P, Sibio S, Biacchi D, et al. (2014). Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis 29:1081–9.
- Takebayashi K, Murata S, Yamamoto H, et al. (2014). Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol 21:1991–7.
- Tentes AA, Stamou K, Pallas N, et al. (2016). The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. Int J Hyperthermia 32:895–9.
- Chouillard E, Ata T, DeJonghe B, et al. (2009). Staged laparoscopic adjuvant intraperitoneal chemohyperthermia after complete resection for locally advanced colorectal or gastric cancer: a preliminary experience. Surg Endosc 23:363–9.
- Baratti D, Kusamura S, Iusco D, et al. (2017). Hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases. Ann Surg Oncol 24:167–75.
- McAuliffe JC, Nash GM. (2017). “Adjuvant” hyperthermic intraperitoneal chemotherapy: a call to action. Ann Surg Oncol 24:11–12.